https://www.appliedxl.com/newshttps://www.appliedxl.com/news/4d-150-diabetic-macular-edema-readout-20262026-07-13T18:00:06.967Zhttps://www.appliedxl.com/news/4d-150-wet-age-related-macular-degeneration-scientific-30723b2026-07-13T17:37:14.433Zhttps://www.appliedxl.com/news/8m2d-alzheimer-s-disease-first-patient-dosed-20262026-07-13T18:11:19.566Zhttps://www.appliedxl.com/news/abcl635-moderate-to-severe-vasomotor-symptoms-vms-associated-with2026-07-13T17:32:26.033Zhttps://www.appliedxl.com/news/abs-201-androgenetic-alopecia-readout-20262026-07-13T17:44:33.796Zhttps://www.appliedxl.com/news/acp-204-alzheimers-disease-psychosis-adp-readout-20262026-07-13T18:42:38.905Zhttps://www.appliedxl.com/news/acumen-pharmaceuticals-inc-sabirnetug-acu193-2026-scientific2026-07-14T16:17:12.841Zhttps://www.appliedxl.com/news/ad109-obstructive-sleep-apnea-fda-decision-20272026-07-13T18:50:59.126Zhttps://www.appliedxl.com/news/adi-001-treatment-refractory-rheumatoid-arthritis-ra-readout-20262026-07-13T17:40:31.232Zhttps://www.appliedxl.com/news/adneuris-therapeutics-cebranopadol-2026-readout2026-07-14T12:45:31.308Zhttps://www.appliedxl.com/news/afrezza-insulin-human-inhalation-powder-type-1-and-type-2-diabetes2026-07-15T21:15:57.097Zhttps://www.appliedxl.com/news/ag-181-phenylketonuria-pku-readout-20262026-07-13T17:55:25.210Zhttps://www.appliedxl.com/news/agmb-447-idiopathic-pulmonary-fibrosis-ipf-readout-20262026-07-13T18:01:52.859Zhttps://www.appliedxl.com/news/aim-immunotech-inc-astrazeneca-erasmus-medical-center-ampligen-2da7912026-07-13T17:38:09.348Zhttps://www.appliedxl.com/news/aim-immunotech-inc-astrazeneca-erasmus-medical-center-ampligen-43b3762026-07-14T17:06:16.378Zhttps://www.appliedxl.com/news/akb-9090-healthy-volunteers-readout-20262026-07-13T18:00:21.651Zhttps://www.appliedxl.com/news/akeso-ak146d1-ak112-nsclc-phase2-20262026-07-14T15:09:16.552Zhttps://www.appliedxl.com/news/akeso-cadonilimab-gastric-phase3-20262026-07-14T15:38:11.199Zhttps://www.appliedxl.com/news/akeso-cadonilimab-nct05256472-rcc-enrollment-cut2026-07-03T17:12:45.325Zhttps://www.appliedxl.com/news/aktis-oncology-inc-aky-1189-2027-readout2026-07-13T18:46:09.331Zhttps://www.appliedxl.com/news/aleniglipron-obesity-and-overweight-readout-20262026-07-13T17:36:49.493Zhttps://www.appliedxl.com/news/alg-000184-chronic-hbv-infection-readout-20262026-07-13T18:00:00.419Zhttps://www.appliedxl.com/news/alkeus-pharmaceuticals-gildeuretinol-2026-scientific-conference2026-07-14T18:46:24.924Zhttps://www.appliedxl.com/news/alkeus-pharmaceuticals-gildeuretinol-2026-scientific-conference-6feb292026-07-14T16:10:38.322Zhttps://www.appliedxl.com/news/allogene-therapeutics-inc-allo-316-2024-readout-f21e422026-07-15T12:45:17.152Zhttps://www.appliedxl.com/news/aln-2232-obesity-and-weight-management-readout-20262026-07-13T18:12:35.830Zhttps://www.appliedxl.com/news/aln-6400-healthy-volunteers-readout-20262026-07-13T17:57:33.015Zhttps://www.appliedxl.com/news/aln-htt02-huntingtons-disease-readout-20262026-07-13T18:32:48.884Zhttps://www.appliedxl.com/news/alpha-dart-newly-diagnosed-pancreatic-cancer-readout-20262026-07-13T18:32:07.343Zhttps://www.appliedxl.com/news/alpha-dart-recurrent-glioblastoma-multiforme-gbm-readout-20262026-07-13T17:55:23.672Zhttps://www.appliedxl.com/news/alpha-dart-recurrent-glioblastoma-multiforme-gbm-trial-enrollment2026-07-13T17:55:24.566Zhttps://www.appliedxl.com/news/alpha-tau-medical-ltd-alpha-dart-pembrolizumab-2026-scientific2026-07-14T18:48:26.288Zhttps://www.appliedxl.com/news/alphamol-alpha-0261-csu-phase1-20262026-07-06T15:56:09.693Zhttps://www.appliedxl.com/news/alto-100-bipolar-depression-bpd-readout-20262026-07-13T17:49:31.537Zhttps://www.appliedxl.com/news/alto-300-major-depressive-disorder-mdd-readout-2026-e8f8c92026-07-13T17:54:54.748Zhttps://www.appliedxl.com/news/alzheimer-s-clinical-trial-consortium-lecanemab-2026-scientific2026-07-14T16:37:13.561Zhttps://www.appliedxl.com/news/alzheon-inc-valiltramiprosate-alz-801-2026-scientific-16f8812026-07-14T16:14:29.416Zhttps://www.appliedxl.com/news/ambelvist-gadoquatrane-contrast-enhanced-mri-to-detect-and-visualize2026-07-15T21:11:06.932Zhttps://www.appliedxl.com/news/amplexd-therapeutics-inc-epigallocatechin-gallate-egcg-based2026-07-13T18:50:27.927Zhttps://www.appliedxl.com/news/anhorn-ah-008-phase-1-july-20262026-07-13T15:44:53.808Zhttps://www.appliedxl.com/news/ani-pharmaceuticals-inc-fluocinolone-acetonide-intravitreal-9253aa2026-07-14T16:14:59.358Zhttps://www.appliedxl.com/news/annexon-inc-vonaprument-2026-readout2026-07-14T20:25:11.150Zhttps://www.appliedxl.com/news/annexon-inc-vonaprument-2026-scientific-conference-presentation2026-07-14T20:25:31.727Zhttps://www.appliedxl.com/news/antengene-selinexor-tislelizumab-touch-nktcl-20262026-07-13T20:15:42.272Zhttps://www.appliedxl.com/news/anzu-cel-anzutresgene-autoleucel-ima203-previously-treated-advanced2026-07-13T18:42:42.761Zhttps://www.appliedxl.com/news/apg777-apg990-moderate-to-severe-atopic-dermatitis-ad-readout-20262026-07-13T17:52:02.077Zhttps://www.appliedxl.com/news/apitegromab-spinal-muscular-atrophy-sma-fda-decision-20262026-07-13T17:36:18.910Zhttps://www.appliedxl.com/news/aqneursa-levacetylleucine-ataxia-telangiectasia-fda-decision-72cc392026-07-13T17:41:12.316Zhttps://www.appliedxl.com/news/aqneursa-levacetylleucine-ataxia-telangiectasia-fda-decision-20262026-07-13T17:41:09.569Zhttps://www.appliedxl.com/news/arakoda-tafenoquine-relapsing-babesiosis-in-immunosuppressed-patients2026-07-13T18:01:28.446Zhttps://www.appliedxl.com/news/arcutis-biotherapeutics-inc-zoryve-foam-0-3-2027-readout2026-07-13T18:49:10.719Zhttps://www.appliedxl.com/news/arcutis-zoryve-cream-pediatric-psoriasis-june-2026-approval-a611c82026-07-15T21:14:00.018Zhttps://www.appliedxl.com/news/ard-101-hyperphagia-associated-with-prader-willi-syndrome-pws-readout2026-07-13T17:40:32.372Zhttps://www.appliedxl.com/news/aro-mapt-early-alzheimers-disease-mild-cognitive-impairment-due-to2026-07-13T18:43:03.030Zhttps://www.appliedxl.com/news/artivion-inc-amds-hybrid-prosthesis-2026-fda-decision2026-07-15T21:09:25.854Zhttps://www.appliedxl.com/news/asc30-type-2-diabetes-mellitus-readout-20262026-07-13T17:42:30.525Zhttps://www.appliedxl.com/news/ascendis-navepegritide-approach-results-20262026-07-14T15:16:14.865Zhttps://www.appliedxl.com/news/ascentage-pelcitoclax-osimertinib-nsclc-phase1b-20262026-07-14T22:15:49.077Zhttps://www.appliedxl.com/news/astellas-pharma-us-inc-asp7317-2026-scientific-conference-presentation2026-07-14T16:06:49.823Zhttps://www.appliedxl.com/news/astellas-pharma-us-inc-izervay-2026-scientific-conference-presentation2026-07-14T16:07:32.548Zhttps://www.appliedxl.com/news/astellas-pharma-us-inc-izervay-readout2026-07-14T16:23:42.876Zhttps://www.appliedxl.com/news/astrazeneca-eplontersen-alxn2220-attriumph-20262026-07-14T15:15:18.640Zhttps://www.appliedxl.com/news/astrazeneca-rilvegostomig-artemide-lung02-2030-completion2026-07-14T15:39:20.490Zhttps://www.appliedxl.com/news/astrazeneca-rilvegostomig-nsclc-enrollment-20262026-07-14T15:39:19.784Zhttps://www.appliedxl.com/news/atacicept-iga-nephropathy-igan-readout-20262026-07-14T16:52:06.377Zhttps://www.appliedxl.com/news/atacicept-immunoglobulin-a-nephropathy-igan-fda-decision-2026-f11f412026-07-15T21:15:17.076Zhttps://www.appliedxl.com/news/ataibeckley-inc-vls-01-2026-readout2026-07-14T16:41:53.779Zhttps://www.appliedxl.com/news/atr-04-egfri-associated-rash-readout-2026-c8fd662026-07-13T17:54:29.242Zhttps://www.appliedxl.com/news/atrasentan-iga-nephropathy-igan-readout-2026-ee0e382026-07-14T16:16:39.480Zhttps://www.appliedxl.com/news/atyr-pharma-inc-efzofitimod-2026-scientific-conference-presentation2026-07-15T12:34:58.600Zhttps://www.appliedxl.com/news/axpaxli-otx-tki-wet-age-related-macular-degeneration-wet-amd-fda2026-07-13T18:39:33.791Zhttps://www.appliedxl.com/news/axsome-therapeutics-solriamfetol-2027-readout2026-07-03T14:29:47.148Zhttps://www.appliedxl.com/news/ba3182-unresectable-or-metastatic-adenocarcinoma-readout-20262026-07-13T18:11:40.520Zhttps://www.appliedxl.com/news/barzolvolimab-prurigo-nodularis-pn-readout-20262026-07-14T17:04:30.882Zhttps://www.appliedxl.com/news/bausch-lomb-corporation-bl1107-2026-readout2026-07-14T16:11:52.638Zhttps://www.appliedxl.com/news/bausch-lomb-lifitegrast-dry-eye-phase2-20262026-07-14T15:25:09.608Zhttps://www.appliedxl.com/news/bbt002-copd-readout-20262026-07-13T17:54:57.467Zhttps://www.appliedxl.com/news/bdc-4182-gastric-and-gastroesophageal-cancer-readout-2026-9c5ff72026-07-13T17:33:14.801Zhttps://www.appliedxl.com/news/beigene-sonrotoclax-mcl-2026-data2026-07-03T17:09:51.474Zhttps://www.appliedxl.com/news/beijing-gene-key-gkl-006allo-phase1-20262026-07-15T15:25:46.893Zhttps://www.appliedxl.com/news/beijing-ql-zovaglutide-qtc-trial-20272026-07-13T15:15:31.377Zhttps://www.appliedxl.com/news/beijing-tiantan-zsneo-dc-glioblastoma-2026-data2026-07-05T19:25:23.187Zhttps://www.appliedxl.com/news/belite-bio-tinlarebant-lbs-008-2026-scientific-conference-presentation2026-07-14T16:16:23.481Zhttps://www.appliedxl.com/news/bepirovirsen-chronic-hepatitis-b-chb-fda-decision-20262026-07-15T21:16:30.253Zhttps://www.appliedxl.com/news/besremi-ropeginterferon-alfa-2b-njft-essential-thrombocythemia-fda2026-07-13T17:32:09.900Zhttps://www.appliedxl.com/news/betta-pharmaceuticals-ensartinib-2026-readout2026-07-14T16:41:24.087Zhttps://www.appliedxl.com/news/beurer-gmbh-bitex-insect-bite-healer-br60-2026-readout2026-07-14T16:18:29.330Zhttps://www.appliedxl.com/news/bezisterim-ne3107-parkinson-s-disease-readout-2026-605bc12026-07-14T17:01:08.420Zhttps://www.appliedxl.com/news/bictegravir-75-mg-lenacapavir-50-mg-bic-len-treatment-of-hiv-in2026-07-13T18:55:26.494Zhttps://www.appliedxl.com/news/biocardia-inc-cardiamp-2026-fda-submission2026-07-13T18:42:35.017Zhttps://www.appliedxl.com/news/biogen-diranersen-biib080-2026-scientific-conference-presentation2026-07-14T16:06:39.701Zhttps://www.appliedxl.com/news/biogen-inc-salanersen-biib115-2026-scientific-conference-presentation2026-07-13T18:08:57.391Zhttps://www.appliedxl.com/news/biomissile-bm230-pd1-trial-20262026-07-13T15:26:25.485Zhttps://www.appliedxl.com/news/biontech-bnt168-hiv-phase-1-trial-20262026-07-13T15:45:12.908Zhttps://www.appliedxl.com/news/biorestorative-therapies-inc-brtx-100-2027-readout2026-07-13T18:30:19.823Zhttps://www.appliedxl.com/news/biostar-utidelone-phase3-nct076844562026-07-06T15:46:44.793Zhttps://www.appliedxl.com/news/bmf-650-overweight-or-obese-participants-readout-20262026-07-13T17:45:12.078Zhttps://www.appliedxl.com/news/bms-986470-sickle-cell-timeline-shift-20262026-07-06T16:05:22.109Zhttps://www.appliedxl.com/news/boehringer-nerandomilast-pirfenidone-interaction-20262026-07-14T15:25:15.017Zhttps://www.appliedxl.com/news/bofanglutide-oral-phase-1-pk-20262026-07-14T22:24:51.939Zhttps://www.appliedxl.com/news/bosakitug-ati-045-moderate-to-severe-atopic-dermatitis-readout-20262026-07-13T18:03:58.413Zhttps://www.appliedxl.com/news/bpl-003-treatment-resistant-depression-trd-readout-20262026-07-13T17:57:09.691Zhttps://www.appliedxl.com/news/budoprutug-immune-thrombocytopenia-itp-readout-2026-37309e2026-07-13T18:48:33.316Zhttps://www.appliedxl.com/news/bv100-habp-vabp-and-settings-with-very-high-drug-resistance-levels2026-07-13T18:02:23.880Zhttps://www.appliedxl.com/news/bysanti-milsaperidone-major-depressive-disorder-mdd-readout-20262026-07-13T17:49:52.547Zhttps://www.appliedxl.com/news/calluna-pharma-as-cal101-2027-readout2026-07-13T18:49:00.865Zhttps://www.appliedxl.com/news/camzyos-mavacamten-symptomatic-obstructive-hypertrophic-1aff082026-07-13T18:54:55.981Zhttps://www.appliedxl.com/news/can-2409-aglatimagene-besadenovec-localized-prostate-cancer-readout2026-07-13T17:39:07.623Zhttps://www.appliedxl.com/news/candel-therapeutics-inc-aglatimagene-besadenovec-can-2409-2026-5cbb272026-07-13T17:32:35.693Zhttps://www.appliedxl.com/news/cardiac-dimensions-carillon-mitral-contour-system-2026-readout2026-07-14T16:19:36.948Zhttps://www.appliedxl.com/news/cartesian-therapeutics-descartes-08-2027-readout2026-07-13T18:46:27.803Zhttps://www.appliedxl.com/news/cbt-001-pterygium-readout-20262026-07-14T16:43:38.041Zhttps://www.appliedxl.com/news/cdx-622-healthy-participants-readout-20262026-07-13T17:37:25.239Zhttps://www.appliedxl.com/news/cellectar-biosciences-inc-iopofosine-i-131-2026-fda-submission2026-07-13T17:32:57.276Zhttps://www.appliedxl.com/news/cellectar-biosciences-inc-iopofosine-i-131-2026-readout2026-07-15T11:46:02.919Zhttps://www.appliedxl.com/news/cervomed-neflamapimod-2025-readout-5f52d42026-07-14T11:55:47.283Zhttps://www.appliedxl.com/news/cervomed-neflamapimod-2026-scientific-conference-presentation-4cb5b72026-07-14T16:16:33.028Zhttps://www.appliedxl.com/news/cervomed-neflamapimod-2027-readout2026-07-13T18:49:34.290Zhttps://www.appliedxl.com/news/chemomab-therapeutics-ltd-cm-101-2022-readout-9c7d232026-07-14T16:31:24.670Zhttps://www.appliedxl.com/news/chengdu-suncadia-hrs-1635-phase-1-july-20262026-07-13T15:44:59.538Zhttps://www.appliedxl.com/news/chengdu-suncadia-hrs-8797-phase1-20262026-07-13T15:44:47.368Zhttps://www.appliedxl.com/news/chia-tai-tianqing-adalimumab-uveitis-20262026-07-15T15:55:30.587Zhttps://www.appliedxl.com/news/chia-tai-tianqing-tq05105-myelofibrosis-phase2-20262026-07-15T15:45:04.621Zhttps://www.appliedxl.com/news/chia-tai-tianqing-tqb2450-eter100-renal-safety-july-20262026-07-03T17:11:03.923Zhttps://www.appliedxl.com/news/chia-tai-tianqing-tqb3126-breast-cancer-trial-20262026-07-13T15:45:33.026Zhttps://www.appliedxl.com/news/chormes-mesoglycan-hemorrhoidal-disease-trial-20262026-07-14T22:34:52.753Zhttps://www.appliedxl.com/news/chronic-pain-scientific-conference-presentation-20262026-07-14T16:24:18.626Zhttps://www.appliedxl.com/news/ciprofol-elderly-pk-pd-study-20262026-07-14T19:44:39.267Zhttps://www.appliedxl.com/news/cl19183-theolim-weight-loss-rct2026-07-15T21:49:36.138Zhttps://www.appliedxl.com/news/claseprubart-dnth103-multifocal-motor-neuropathy-mmn-readout-20262026-07-13T18:04:03.412Zhttps://www.appliedxl.com/news/clemizole-hydrochloride-epx-100-dravet-syndrome-readout-20262026-07-03T14:19:29.788Zhttps://www.appliedxl.com/news/cln-978-rheumatoid-arthritis-ra-readout-20262026-07-13T17:38:18.257Zhttps://www.appliedxl.com/news/cnm-au8-als-fda-submission-20262026-07-13T17:35:06.934Zhttps://www.appliedxl.com/news/cochlear-limited-osia-3-sound-processor-2026-readout2026-07-14T16:04:52.960Zhttps://www.appliedxl.com/news/codex-labs-corporation-bia-skin-barrier-supplement-and-plant-biotech2026-07-14T16:35:07.464Zhttps://www.appliedxl.com/news/cognition-therapeutics-inc-zervimesine-ct1812-2026-scientific2026-07-14T16:37:33.094Zhttps://www.appliedxl.com/news/cognition-therapeutics-inc-zervimesine-ct1812-2026-scientific-11a0bd2026-07-14T16:14:03.568Zhttps://www.appliedxl.com/news/compass-pathways-plc-comp360-psilocybin-2026-readout-d2d06a2026-07-14T16:50:21.118Zhttps://www.appliedxl.com/news/conferenceshttps://www.appliedxl.com/news/corxel-etripamil-nasal-spray-2026-fda-decision2026-07-13T18:55:13.865Zhttps://www.appliedxl.com/news/coya-therapeutics-inc-coya-302-2027-readout2026-07-13T18:51:12.261Zhttps://www.appliedxl.com/news/createrna-qr12000-phase2-hypertension-20232026-07-14T15:15:41.313Zhttps://www.appliedxl.com/news/cretostimogene-grenadenorepvec-high-risk-nonmuscle-invasive-bladder2026-07-13T18:42:44.101Zhttps://www.appliedxl.com/news/cretostimogene-grenadenorepvec-intermediate-risk-non-muscle-invasive2026-07-15T21:14:54.835Zhttps://www.appliedxl.com/news/cspc-megalith-sys6026-phase2-hpv-cervical-lesions2026-07-14T15:34:58.479Zhttps://www.appliedxl.com/news/cspc-ouyi-syh9089-phase1-recruiting-20262026-07-15T15:35:02.019Zhttps://www.appliedxl.com/news/ctrp7-dapagliflozin-diabetic-kidney-disease-20262026-07-14T22:54:53.086Zhttps://www.appliedxl.com/news/ctx611-srsd107-patients-undergoing-total-knee-arthroplasty-tka2026-07-13T17:55:25.074Zhttps://www.appliedxl.com/news/curis-inc-emavusertib-zanubrutinib-2026-first-patient-dosed2026-07-14T17:05:57.015Zhttps://www.appliedxl.com/news/cyb003-adjunctive-treatment-of-major-depressive-disorder-readout-20262026-07-13T17:56:06.730Zhttps://www.appliedxl.com/news/cyllene-therapeutics-eg110a-2026-readout2026-07-14T16:30:31.299Zhttps://www.appliedxl.com/news/cytisinicline-smoking-cessation-in-adults-fda-decision-2026-8b255b2026-07-15T21:13:15.486Zhttps://www.appliedxl.com/news/d-plex100-prevention-of-surgical-site-infections-ssis-in-2f16252026-07-13T18:34:55.535Zhttps://www.appliedxl.com/news/da-1726-obesity-obese-otherwise-healthy-adult-subjects-readout-20262026-07-13T17:58:07.036Zhttps://www.appliedxl.com/news/delpacibart-braxlosiran-del-brax-facioscapulohumeral-muscular-515bf82026-07-13T17:53:02.960Zhttps://www.appliedxl.com/news/dexmedetomidine-laparoscopic-surgery-sleep2026-07-15T21:16:35.071Zhttps://www.appliedxl.com/news/disc-0974-anemia-of-myelofibrosis-mf-readout-20262026-07-13T17:53:10.995Zhttps://www.appliedxl.com/news/disc-3405-polycythemia-vera-pv-readout-20262026-07-13T17:45:51.741Zhttps://www.appliedxl.com/news/disc-3405-sickle-cell-disease-scd-readout-20262026-07-13T17:35:49.252Zhttps://www.appliedxl.com/news/dnth103-chronic-inflammatory-demyelinating-polyneuropathy-cidp2026-07-13T18:03:15.083Zhttps://www.appliedxl.com/news/dnth212-lbl-047-healthy-volunteers-part-a-readout-20262026-07-13T17:53:56.908Zhttps://www.appliedxl.com/news/dogwood-therapeutics-halneuron-2026-readout2026-07-13T17:58:15.362Zhttps://www.appliedxl.com/news/dragonboat-ldp-cdp1-2026-enrollment-cut2026-07-06T15:56:55.527Zhttps://www.appliedxl.com/news/dragonboat-ldp-nct04718584-enrollment-cut2026-07-06T15:36:37.297Zhttps://www.appliedxl.com/news/dragonboat-ldp-pd-l1-enrollment-cut-20262026-07-06T15:47:21.621Zhttps://www.appliedxl.com/news/dt-216p2-friedreich-ataxia-fa-readout-20262026-07-13T17:50:04.952Zhttps://www.appliedxl.com/news/dt120-lysergide-odt-100-g-major-depressive-disorder-mdd-824d9d2026-07-15T21:14:19.617Zhttps://www.appliedxl.com/news/dtx401-pariglasgene-brecaparvovec-glycogen-storage-disease-type-ia2026-07-15T21:15:20.047Zhttps://www.appliedxl.com/news/dyne-therapeutics-z-basivarsen-2027-readout2026-07-13T18:48:11.366Zhttps://www.appliedxl.com/news/ecog-acrin-cancer-research-ecog-acrin-lenalidomide-2026-nct018635502026-07-15T21:25:11.341Zhttps://www.appliedxl.com/news/eisai-lecanemab-irmb-2025-fda-decision-2dc0f02026-07-14T16:09:42.943Zhttps://www.appliedxl.com/news/eledon-pharmaceuticals-inc-tegoprubart-readout2026-07-14T16:46:21.085Zhttps://www.appliedxl.com/news/eli-lilly-canada-inc-ebglyss-lebrikizumab-2026-readout2026-07-14T16:30:42.737Zhttps://www.appliedxl.com/news/elsunersen-early-seizure-onset-scn2a-dee-readout-20262026-07-13T17:42:27.879Zhttps://www.appliedxl.com/news/elysium-health-inc-basis-2026-readout2026-07-14T16:05:24.082Zhttps://www.appliedxl.com/news/endevica-mifomelatide-tcmcb07-2027-timing2026-07-15T15:35:04.544Zhttps://www.appliedxl.com/news/ennovabio-enc0653-phase1-trial-20262026-07-06T15:45:23.320Zhttps://www.appliedxl.com/news/eo2463-follicular-lymphoma-and-marginal-zone-lymphoma-scientific2026-07-14T18:46:12.355Zhttps://www.appliedxl.com/news/ep-104gi-eosinophilic-esophagitis-eoe-readout-20262026-07-13T18:55:02.420Zhttps://www.appliedxl.com/news/eplontersen-attr-cardiomyopathy-readout-2026-c4fd8a2026-07-14T16:19:51.834Zhttps://www.appliedxl.com/news/escitalopram-vortioxetine-depression-comparison2026-07-15T20:54:44.811Zhttps://www.appliedxl.com/news/esk-001-systemic-lupus-erythematosus-sle-readout-20262026-07-13T17:43:16.912Zhttps://www.appliedxl.com/news/esophageal-cancer-radiation-dose-escalation-long-term-outcomes2026-07-14T22:44:51.070Zhttps://www.appliedxl.com/news/eupraxia-pharmaceuticals-inc-ep-104gi-2026-readout2026-07-14T17:07:24.951Zhttps://www.appliedxl.com/news/evo756-adults-with-moderate-to-severe-atopic-dermatitis-readout-20262026-07-13T18:40:03.840Zhttps://www.appliedxl.com/news/fasedienol-nasal-spray-social-anxiety-disorder-readout-2026-a3159c2026-07-15T21:10:58.326Zhttps://www.appliedxl.com/news/fasedienol-social-anxiety-disorder-readout-20262026-07-13T17:38:21.066Zhttps://www.appliedxl.com/news/fb102-vitiligo-readout-2026-93b7b12026-07-14T16:18:04.882Zhttps://www.appliedxl.com/news/fujian-shengdi-hrs9531-t2d-phase3-completion-20262026-07-14T15:05:34.423Zhttps://www.appliedxl.com/news/futuregen-fg-m108-fg-b901-2026-trial-initiation2026-07-15T15:25:46.341Zhttps://www.appliedxl.com/news/garetosmab-adults-with-fibrodysplasia-ossificans-progressiva-fop-fda2026-07-15T21:17:24.410Zhttps://www.appliedxl.com/news/gb-0669-first-in-human-20262026-07-14T19:34:52.375Zhttps://www.appliedxl.com/news/gcar1-gpnmb-cart-aspc-2026-readout2026-07-03T17:09:20.971Zhttps://www.appliedxl.com/news/gedatolisib-hormone-receptor-positive-hr-her2-pik3ca-wild-type2026-07-14T16:51:58.027Zhttps://www.appliedxl.com/news/gedatolisib-hormone-receptor-positive-hr-her2-pik3ca-wild-type-5c79712026-07-14T21:15:47.981Zhttps://www.appliedxl.com/news/gensci144-pku-phase1-china-20262026-07-06T15:45:42.325Zhttps://www.appliedxl.com/news/gensciences-frsw107-phase3-20272026-07-06T15:35:57.838Zhttps://www.appliedxl.com/news/glix1-recurrent-and-progressive-glioblastoma-gbm-and-other-high-grade2026-07-13T18:23:26.146Zhttps://www.appliedxl.com/news/glm101-phosphomannomutase-2-congenital-disorder-of-434bfc2026-07-13T17:55:44.509Zhttps://www.appliedxl.com/news/gsk-depemokimab-japan-crswnp-monotherapy-20272026-07-14T15:15:53.797Zhttps://www.appliedxl.com/news/gst-hg171-renal-impairment-pk-20262026-07-15T19:35:05.366Zhttps://www.appliedxl.com/news/gtx-102-angelman-syndrome-readout-20262026-07-13T17:47:13.217Zhttps://www.appliedxl.com/news/guangdong-hongzhi-cgf-knee-osteoarthritis-20262026-07-07T15:25:33.246Zhttps://www.appliedxl.com/news/gubra-gub-ucn2-first-in-human-trial-20262026-07-14T15:26:52.841Zhttps://www.appliedxl.com/news/haisco-hsk41959-combination-trial-20262026-07-13T15:25:24.142Zhttps://www.appliedxl.com/news/hangzhou-zhongmei-roflumilast-china-20272026-07-06T15:45:52.859Zhttps://www.appliedxl.com/news/hansoh-hs-20122-nsclc-phase1b-20262026-07-06T15:56:06.637Zhttps://www.appliedxl.com/news/harmony-biosciences-holdings-inc-epx-100-clemizole-hydrochloride-20272026-07-03T14:18:55.599Zhttps://www.appliedxl.com/news/hengrui-hrs-4642-pancreatic-cancer-phase-3-recruiting2026-07-15T15:25:18.236Zhttps://www.appliedxl.com/news/hengrui-pharma-hrs-7535-kai-7535-2026-readout2026-07-14T16:28:02.242Zhttps://www.appliedxl.com/news/hengrui-pharma-hrs-7535-kai-7535-2026-readout-9ff1ee2026-07-14T16:27:32.301Zhttps://www.appliedxl.com/news/hengrui-shr-1703-autoinjector-pk-study-20272026-07-14T15:24:58.664Zhttps://www.appliedxl.com/news/hengrui-shr-a1811-horizon-breast01-2026-interim-data2026-07-03T17:10:15.540Zhttps://www.appliedxl.com/news/huadong-roflumilast-cream-china-phase3-20252026-07-06T16:06:28.730Zhttps://www.appliedxl.com/news/huilun-hl-1186-postoperative-pain-trial-20262026-07-13T15:25:10.787Zhttps://www.appliedxl.com/news/hutchmed-hmpl-453-fanregratinib-ddi-study-20252026-07-13T15:25:13.393Zhttps://www.appliedxl.com/news/hutchmed-hmpl-760-pk-study-20262026-07-13T15:34:58.922Zhttps://www.appliedxl.com/news/huyabio-international-hbi-8000-in-combination-with-nivolumab-20262026-07-14T12:15:38.212Zhttps://www.appliedxl.com/news/icvax-hiv-dna-vaccine-phase-1-results-20262026-07-14T19:25:11.463Zhttps://www.appliedxl.com/news/ima203-unresectable-or-metastatic-cutaneous-melanoma-who-have-a9be8c2026-07-13T18:29:37.667Zhttps://www.appliedxl.com/news/ima402-prame-bispecific-melanoma-gynecologic-cancers-readout-20262026-07-13T18:35:05.425Zhttps://www.appliedxl.com/news/imbioray-ibr733-aml-timeline-delay-20272026-07-03T17:09:46.571Zhttps://www.appliedxl.com/news/imbioray-ibr854-phase1-solid-tumors-20262026-07-06T19:26:12.465Zhttps://www.appliedxl.com/news/imc-p115c-multiple-solid-tumors-per-pr-readout-20262026-07-13T18:45:56.572Zhttps://www.appliedxl.com/news/imc-p115c-prame-a02-hle-multiple-solid-tumors-scientific-conference2026-07-13T18:45:58.597Zhttps://www.appliedxl.com/news/img-007-moderate-to-severe-atopic-dermatitis-readout-20262026-07-13T17:38:41.413Zhttps://www.appliedxl.com/news/immix-biopharma-inc-nxc-201-2026-scientific-conference-presentation2026-07-13T17:33:17.589Zhttps://www.appliedxl.com/news/immix-biopharma-inc-nxc-201-2027-readout2026-07-13T18:31:52.943Zhttps://www.appliedxl.com/news/immunobrain-ibc-ab002-2026-readout2026-07-14T14:25:16.269Zhttps://www.appliedxl.com/news/imp761-healthy-participants-readout-20262026-07-13T17:36:25.807Zhttps://www.appliedxl.com/news/incb160058-myeloproliferative-neoplasms-mpn-with-jak2v617f-mutation2026-07-13T17:42:41.036Zhttps://www.appliedxl.com/news/incretin-therapies-muscle-mass-obesity2026-07-15T21:50:00.377Zhttps://www.appliedxl.com/news/innocare-orelabrutinib-cll-phase3-2026-data2026-07-06T20:55:48.222Zhttps://www.appliedxl.com/news/innocare-pharma-soficitinib-icp-332-2026-readout-7ad8f02026-07-15T12:06:04.339Zhttps://www.appliedxl.com/news/innovent-ibi3031-thyroid-eye-disease-phase1-20262026-07-14T15:15:24.037Zhttps://www.appliedxl.com/news/insilico-medicine-rentosertib-2026-readout2026-07-14T16:22:29.538Zhttps://www.appliedxl.com/news/insilico-rentosertib-ipf-phase3-20262026-07-07T15:25:37.834Zhttps://www.appliedxl.com/news/intercept-blood-system-for-red-blood-cells-rbcs-patient-populations2026-07-13T18:34:15.477Zhttps://www.appliedxl.com/news/intercept-rbcs-fda-submission-20262026-07-13T18:34:52.404Zhttps://www.appliedxl.com/news/intercept-red-blood-cells-fda-submission-20262026-07-13T18:34:24.810Zhttps://www.appliedxl.com/news/intraoperative-hypothermia-tcm-constitution-warming-blanket-20262026-07-14T19:34:46.258Zhttps://www.appliedxl.com/news/inventiva-lanifibranor-2027-readout2026-07-13T18:51:49.516Zhttps://www.appliedxl.com/news/inxmed-co-ltd-ifebemtinib-in10018-garsorasib-d-1553-2026-readout2026-07-14T16:29:36.764Zhttps://www.appliedxl.com/news/ipsen-dysport-abobotulinumtoxina-2026-readout2026-07-14T16:29:09.339Zhttps://www.appliedxl.com/news/ipsen-dysport-abobotulinumtoxina-2026-readout-2c2ae12026-07-14T16:40:03.112Zhttps://www.appliedxl.com/news/irenix-medical-inc-irx-101-2026-readout2026-07-14T16:21:54.813Zhttps://www.appliedxl.com/news/iv-choline-chloride-patients-receiving-long-term-parenteral-support2026-07-13T17:54:24.872Zhttps://www.appliedxl.com/news/ivarmacitinib-atopic-dermatitis-early-response-analysis2026-07-15T19:45:54.480Zhttps://www.appliedxl.com/news/iveric-bio-inc-zimura-avacincaptad-pegol-2022-readout-23baec2026-07-14T16:23:43.617Zhttps://www.appliedxl.com/news/ivonescimab-h3k27m-dmg-pilot-20262026-07-14T19:14:50.167Zhttps://www.appliedxl.com/news/jacobio-jab-8263-rheumatoid-arthritis-20262026-07-06T15:47:30.989Zhttps://www.appliedxl.com/news/janx011-healthy-volunteers-readout-20262026-07-13T17:41:53.952Zhttps://www.appliedxl.com/news/jenscare-lux-valve-plus-tricuspid-2026-readout2026-07-15T15:35:17.412Zhttps://www.appliedxl.com/news/johnson-johnson-erleada-apalutamide-readout2026-07-15T10:46:21.761Zhttps://www.appliedxl.com/news/johnson-johnson-nipocalimab-nipocalimab-aahu-readout2026-07-15T10:45:49.014Zhttps://www.appliedxl.com/news/junshi-toripalimab-neotorch-surgical-outcomes-20262026-07-15T19:15:04.422Zhttps://www.appliedxl.com/news/kairos-pharma-ltd-env-105-carotuximab-2026-readout2026-07-15T12:44:47.904Zhttps://www.appliedxl.com/news/karyopharm-selinexor-stomp-mezigdomide-20262026-07-15T15:55:28.787Zhttps://www.appliedxl.com/news/kb407-cystic-fibrosis-cf-readout-20262026-07-13T17:56:03.830Zhttps://www.appliedxl.com/news/keenova-therapeutics-plc-xiaflex-collagenase-clostridium-d7d0ea2026-07-14T16:22:01.559Zhttps://www.appliedxl.com/news/kelun-biotech-cr-003-skb105-2027-readout2026-07-13T18:32:19.918Zhttps://www.appliedxl.com/news/kelun-biotech-sacituzumab-tirumotecan-sac-tmt-in-combination-with2026-07-14T23:45:37.783Zhttps://www.appliedxl.com/news/kelun-biotech-skb264-skb118-nsclc-trial-20262026-07-13T15:36:23.934Zhttps://www.appliedxl.com/news/kelun-biotech-skb500-esophageal-trial-20262026-07-14T15:16:05.390Zhttps://www.appliedxl.com/news/keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph-and-5178432026-07-14T18:48:51.126Zhttps://www.appliedxl.com/news/kodiak-sciences-inc-ksi-101-2027-readout2026-07-13T18:15:41.572Zhttps://www.appliedxl.com/news/kpl-387-recurrent-pericarditis-readout-20262026-07-13T17:43:33.639Zhttps://www.appliedxl.com/news/ksi-101-macular-edema-secondary-to-inflammation-mesi-readout-20262026-07-13T18:40:00.812Zhttps://www.appliedxl.com/news/kura-oncology-inc-darlifarnib-plus-cabozantinib-2026-scientific2026-07-14T11:15:50.702Zhttps://www.appliedxl.com/news/lantern-pharma-inc-lp-300-2026-readout2026-07-13T17:48:18.112Zhttps://www.appliedxl.com/news/larkspur-lrk-4189-recruiting-20262026-07-13T15:25:09.088Zhttps://www.appliedxl.com/news/laromestrocel-lomecel-b-hypoplastic-left-heart-syndrome-hlhs-readout2026-07-14T16:44:11.897Zhttps://www.appliedxl.com/news/laru-zova-x-linked-retinitis-pigmentosa-xlrp-readout-20262026-07-13T18:43:39.423Zhttps://www.appliedxl.com/news/lbl-024-first-line-non-small-cell-lung-cancer-nsclc-scientific2026-07-13T17:40:54.008Zhttps://www.appliedxl.com/news/leniolisib-genetically-defined-primary-immunodeficiencies-pids-linked2026-07-14T17:01:59.504Zhttps://www.appliedxl.com/news/lenz-therapeutics-inc-lnz100-2027-fda-decision2026-07-13T18:50:42.291Zhttps://www.appliedxl.com/news/leo-pharma-a-s-tralokinumab-2026-readout2026-07-14T16:11:42.384Zhttps://www.appliedxl.com/news/lexicon-pharmaceuticals-inc-sotagliflozin-2027-readout2026-07-13T18:50:39.015Zhttps://www.appliedxl.com/news/lifemine-life-001-phase1-2026-enrollment2026-07-07T15:26:00.931Zhttps://www.appliedxl.com/news/lifileucel-post-anti-pd-1-non-small-cell-lung-cancer-nsclc-fda2026-07-13T18:32:34.889Zhttps://www.appliedxl.com/news/lilly-bimagrumab-semaglutide-obesity-readout-nct056160132026-07-15T21:51:35.066Zhttps://www.appliedxl.com/news/lilly-bimagrumab-semaglutide-obesity-readout-nct05616013-a0f1ad2026-07-15T21:51:36.555Zhttps://www.appliedxl.com/news/lingyi-biotech-ly-n001-2026-trial-initiation2026-07-06T16:06:44.289Zhttps://www.appliedxl.com/news/lirafugratinib-cholangiocarcinoma-cca-with-fgfr2-fusions-or2026-07-13T18:55:52.857Zhttps://www.appliedxl.com/news/lncb74-advanced-solid-tumors-higher-dose-cohorts-prioritize-breast2026-07-13T18:29:17.934Zhttps://www.appliedxl.com/news/lncb74-advanced-solid-tumors-readout-20262026-07-13T17:54:40.655Zhttps://www.appliedxl.com/news/lti-03-idiopathic-pulmonary-fibrosis-ipf-readout-2026-1df85d2026-07-13T17:34:18.044Zhttps://www.appliedxl.com/news/lumateperone-china-pharmacokinetics-20262026-07-15T19:34:45.823Zhttps://www.appliedxl.com/news/maat013-acute-graftversushost-disease-agvhd-fda-decision-20262026-07-13T18:41:25.169Zhttps://www.appliedxl.com/news/mbx-4291-obesity-readout-20262026-07-13T17:36:37.497Zhttps://www.appliedxl.com/news/md-anderson-nautilus-lutetium-2026-recruiting2026-07-15T15:54:55.672Zhttps://www.appliedxl.com/news/medicinova-2026-readout2026-07-14T16:58:46.839Zhttps://www.appliedxl.com/news/memorial-sloan-kettering-cancer-center-ser-155-2026-readout-c9b6ed2026-07-14T16:21:42.982Zhttps://www.appliedxl.com/news/merck-islatravir-and-lenacapavir-isl-len-2026-scientific-01587f2026-07-15T11:25:28.452Zhttps://www.appliedxl.com/news/merck-islatravir-and-lenacapavir-isl-len-2026-scientific-conference2026-07-15T11:25:58.596Zhttps://www.appliedxl.com/news/merck-islatravir-and-ulonivirine-isl-ulo-2026-scientific-conference2026-07-15T11:25:30.898Zhttps://www.appliedxl.com/news/merck-keytruda-pembrolizumab-2026-readout2026-07-15T11:08:15.046Zhttps://www.appliedxl.com/news/miach-orthopaedics-inc-bear-implant-readout2026-07-14T16:18:38.276Zhttps://www.appliedxl.com/news/mighty-therapeutics-elamipretide-2026-scientific-conference2026-07-14T16:07:43.670Zhttps://www.appliedxl.com/news/minghui-mh004-vitiligo-phase3-20262026-07-06T15:46:34.104Zhttps://www.appliedxl.com/news/mitapivat-sickle-cell-disease-regulatory-designation-20262026-07-13T18:55:21.062Zhttps://www.appliedxl.com/news/miv-cel-stiff-person-syndrome-sps-readout-20262026-07-03T13:48:41.311Zhttps://www.appliedxl.com/news/ml-007c-ma-schizophrenia-readout-20262026-07-14T16:24:08.640Zhttps://www.appliedxl.com/news/mn-001-tipelukast-hypertriglyceridemia-and-non-alcoholic-fatty-liver2026-07-14T17:06:09.974Zhttps://www.appliedxl.com/news/moderna-mrna-1010-mrna-1083-2026-fda-decision2026-07-13T17:43:13.424Zhttps://www.appliedxl.com/news/mr-100a-01-contraception-in-women-of-childbearing-potential-bmi-30-kg2026-07-14T16:31:22.174Zhttps://www.appliedxl.com/news/mr-107a-02-fast-acting-meloxicam-moderate-to-severe-acute-pain-fda2026-07-13T17:42:51.621Zhttps://www.appliedxl.com/news/mr-142-phentolamine-ophthalmic-solution-0-75-significant-chronic2026-07-15T21:16:35.203Zhttps://www.appliedxl.com/news/mresvia-rsv-readout-20262026-07-13T17:45:45.222Zhttps://www.appliedxl.com/news/mrna-1010-seasonal-influenza-fda-decision-20262026-07-14T16:29:56.725Zhttps://www.appliedxl.com/news/mrna-1010-seasonal-influenza-fda-submission-20262026-07-13T17:43:14.024Zhttps://www.appliedxl.com/news/mrt-8102-elevated-cardiovascular-disease-cvd-risk-readout-20262026-07-13T17:56:16.332Zhttps://www.appliedxl.com/news/multitude-therapeutics-amt-116-ivonescimab-2026-trial-open2026-07-14T15:19:37.368Zhttps://www.appliedxl.com/news/nanoscope-therapeutics-inc-mco-010-2026-scientific-conference2026-07-10T13:15:08.453Zhttps://www.appliedxl.com/news/navacaprant-major-depressive-disorder-readout-20262026-07-15T21:18:28.340Zhttps://www.appliedxl.com/news/ndv-01-second-line-2l-bcg-unresponsive-nmibc-readout-20262026-07-13T18:40:59.475Zhttps://www.appliedxl.com/news/nedaplatin-paclitaxel-esophageal-cancer-2026-phase22026-07-14T19:34:52.854Zhttps://www.appliedxl.com/news/nektar-therapeutics-rezpegaldesleukin-2026-readout2026-07-14T16:58:17.225Zhttps://www.appliedxl.com/news/nektar-therapeutics-rezpegaldesleukin-2027-readout2026-07-03T14:23:38.745Zhttps://www.appliedxl.com/news/neonc-technologies-holdings-inc-neo100-2026-readout2026-07-14T17:00:11.142Zhttps://www.appliedxl.com/news/neonc-technologies-holdings-neo100-2026-readout2026-07-13T18:55:00.680Zhttps://www.appliedxl.com/news/neumora-navacaprant-koastal-3-2026-completion2026-07-06T15:55:32.001Zhttps://www.appliedxl.com/news/neurothera-labs-inc-sci-110-2026-readout2026-07-15T12:55:18.635Zhttps://www.appliedxl.com/news/newamsterdam-pharma-company-n-v-obicetrapib-2026-scientific-4d9d432026-07-14T16:16:19.080Zhttps://www.appliedxl.com/news/newamsterdam-pharma-company-n-v-obicetrapib-2026-scientific-90d0282026-07-14T16:16:24.755Zhttps://www.appliedxl.com/news/nexcella-nxc-201-al-amyloidosis-20262026-07-14T15:25:07.926Zhttps://www.appliedxl.com/news/nih-brainhq-exercises-readout2026-07-14T16:05:07.295Zhttps://www.appliedxl.com/news/ninerafaxstat-non-obstructive-hypertrophic-cardiomyopathy-nhcm2026-07-13T17:55:58.936Zhttps://www.appliedxl.com/news/nintedanib-dpi-mnkd-201-readout-20262026-07-12T00:05:20.294Zhttps://www.appliedxl.com/news/nmra-511-alzheimer-s-disease-agitation-readout-20262026-07-13T17:43:04.448Zhttps://www.appliedxl.com/news/nocion-therapeutics-inc-taplucainium-2026-scientific-conference2026-07-14T16:10:50.310Zhttps://www.appliedxl.com/news/npm-139-obesity-readout-20262026-07-13T18:34:25.525Zhttps://www.appliedxl.com/news/nuc-7738-pd-1-inhibitor-resistant-metastatic-melanoma-readout-20262026-07-13T17:51:20.774Zhttps://www.appliedxl.com/news/nutrafol-nutrafol-s-hair-growth-nutraceuticals-2026-readout2026-07-15T13:25:04.409Zhttps://www.appliedxl.com/news/nxera-pharma-daridorexant-2027-fda-decision2026-07-13T18:50:54.098Zhttps://www.appliedxl.com/news/ocs-01-diabetic-macular-edema-readout-2026-8e97142026-07-15T21:16:41.981Zhttps://www.appliedxl.com/news/octapharma-usa-wilate-2026-readout2026-07-14T16:38:53.908Zhttps://www.appliedxl.com/news/ocu400-retinitis-pigmentosa-fda-decision-20262026-07-15T21:13:56.920Zhttps://www.appliedxl.com/news/ocu410st-stargardt-disease-st-readout-20262026-07-13T17:32:12.235Zhttps://www.appliedxl.com/news/ocugen-inc-ocu400-2027-readout2026-07-13T18:33:52.826Zhttps://www.appliedxl.com/news/ocugen-ocu410-2026-scientific-conference-presentation2026-07-14T16:05:31.252Zhttps://www.appliedxl.com/news/ocugen-ocu410-2026-scientific-conference-presentation-9be1d22026-07-14T16:42:45.225Zhttps://www.appliedxl.com/news/ollin-biosciences-oln324-2026-scientific-conference-fd1d612026-07-14T16:41:27.683Zhttps://www.appliedxl.com/news/ollin-biosciences-oln324-2026-scientific-conference-presentation2026-07-14T16:06:46.674Zhttps://www.appliedxl.com/news/olvi-vec-platinum-resistant-refractory-ovarian-cancer-readout-20262026-07-11T00:05:22.993Zhttps://www.appliedxl.com/news/onkure-oki-219-2026-readout-timing2026-07-06T15:55:46.026Zhttps://www.appliedxl.com/news/onkure-oki-219-pikture-01-2026-enrollment-complete2026-07-06T16:05:42.409Zhttps://www.appliedxl.com/news/onp-002-concussion-mild-traumatic-brain-injury-mtbi-readout-20262026-07-13T18:07:58.246Zhttps://www.appliedxl.com/news/onp-002-concussion-mild-traumatic-brain-injury-mtbi-readout-1469272026-07-14T16:21:53.238Zhttps://www.appliedxl.com/news/ontunisertib-agmb-129-fibrostenosing-crohns-disease-fscd-readout-20262026-07-13T18:11:28.738Zhttps://www.appliedxl.com/news/opakalim-focal-epilepsy-readout-20262026-07-13T17:42:56.527Zhttps://www.appliedxl.com/news/opakalim-refractory-focal-epilepsy-readout-20262026-07-13T17:39:51.080Zhttps://www.appliedxl.com/news/oral-pill-vaccine-covid-19-readout-2026-f957742026-07-03T14:01:33.829Zhttps://www.appliedxl.com/news/orasis-pharmaceuticals-beska-pilocarpine-hydrochloride-ophthalmic2026-07-15T13:35:18.719Zhttps://www.appliedxl.com/news/orca-bio-orca-t-2026-fda-decision-17706b2026-07-15T21:17:13.388Zhttps://www.appliedxl.com/news/organon-vtama-cream-tapinarof-2026-scientific-conference-presentation2026-07-14T16:16:39.969Zhttps://www.appliedxl.com/news/orka-001-moderate-to-severe-psoriasis-readout-20262026-07-13T17:49:23.229Zhttps://www.appliedxl.com/news/orziloben-intestinal-failure-associated-liver-disease-ifald-readout2026-07-13T17:32:10.483Zhttps://www.appliedxl.com/news/otsuka-pharmaceutical-development-commercialization-inc-and-0ec9f02026-07-15T21:17:58.519Zhttps://www.appliedxl.com/news/otsuka-pharmaceutical-development-commercialization-inc-and-otsuka2026-07-15T21:17:36.761Zhttps://www.appliedxl.com/news/otsuka-pharmaceutical-development-commercialization-inc-otsuka2026-07-15T21:18:51.922Zhttps://www.appliedxl.com/news/ozekibart-inbrx-109-unresectable-or-metastatic-conventional-d0416b2026-07-13T18:51:38.420Zhttps://www.appliedxl.com/news/padeliporfin-vtp-low-grade-upper-tract-urothelial-carcinoma-utuc-fda2026-07-13T18:44:21.487Zhttps://www.appliedxl.com/news/pascal-tricuspid-regurgitation-tr-fda-decision-20262026-07-13T18:08:46.157Zhttps://www.appliedxl.com/news/patas-type-2-diabetes-readout-20262026-07-13T18:00:36.222Zhttps://www.appliedxl.com/news/pdl1-gastric-cancer-metastasis-histology-meta-analysis-20262026-07-14T20:54:43.503Zhttps://www.appliedxl.com/news/peg-bio-ft1-short-bowel-syndrome-phase2-20262026-07-15T15:25:04.403Zhttps://www.appliedxl.com/news/peg-bio-pa5-phase1-20262026-07-14T15:15:00.864Zhttps://www.appliedxl.com/news/pegtibatinase-classical-homocystinuria-hcu-readout-20262026-07-14T16:49:29.297Zhttps://www.appliedxl.com/news/pelacarsen-lp-a-cardiovascular-outcomes-readout-20262026-07-15T21:11:36.727Zhttps://www.appliedxl.com/news/pemvidutide-aud-readout-20262026-07-14T16:49:44.417Zhttps://www.appliedxl.com/news/pevifoscorvir-sodium-alg-000184-chronic-hepatitis-b-virus-hbv2026-07-13T17:39:13.780Zhttps://www.appliedxl.com/news/pfizer-atirmociclib-nct06465368-phase2-results2026-07-15T15:45:42.407Zhttps://www.appliedxl.com/news/pgn-edodm1-myotonic-dystrophy-type-1-dm1-readout-20262026-07-13T18:10:09.446Zhttps://www.appliedxl.com/news/pharmasaga-ps1-phase-1-completion-20262026-07-07T15:25:35.236Zhttps://www.appliedxl.com/news/plus-therapeutics-inc-reyobiq-rhenium-re186-obisbemeda-2027-readout2026-07-13T18:11:15.617Zhttps://www.appliedxl.com/news/pmn310-stage-3-and-stage-4-alzheimer-s-disease-readout-20262026-07-12T00:05:10.859Zhttps://www.appliedxl.com/news/povetacicept-immunoglobulin-a-nephropathy-igan-fda-decision-20262026-07-13T17:44:18.483Zhttps://www.appliedxl.com/news/povorcitinib-asthma-readout-20262026-07-14T16:58:19.668Zhttps://www.appliedxl.com/news/profound-medical-corp-tulsa-procedure-2026-scientific-52b8ea2026-07-15T12:05:08.738Zhttps://www.appliedxl.com/news/profound-medical-corp-tulsa-procedure-2026-scientific-conference2026-07-15T12:05:01.472Zhttps://www.appliedxl.com/news/promis-neurosciences-inc-pmn310-2027-readout2026-07-12T00:05:06.782Zhttps://www.appliedxl.com/news/prosense-breast-cancer-fda-submission-2026-4758122026-07-13T18:03:04.859Zhttps://www.appliedxl.com/news/prosense-cryoablation-system-early-stage-low-risk-invasive-breast2026-07-13T18:08:08.881Zhttps://www.appliedxl.com/news/prula-cel-systemic-sclerosis-readout-20262026-07-13T18:09:12.307Zhttps://www.appliedxl.com/news/pva-microsphere-rhinoplasty-2026-case-study2026-07-13T20:04:48.868Zhttps://www.appliedxl.com/news/q32-bio-inc-bempikibart-adx-914-2026-readout-cc458f2026-07-14T16:09:42.487Zhttps://www.appliedxl.com/news/quantx-qx-4533-phase1-recruiting-20262026-07-07T15:25:19.388Zhttps://www.appliedxl.com/news/quince-therapeutics-lam-001-2027-readout2026-07-13T18:49:20.177Zhttps://www.appliedxl.com/news/r289-relapsed-or-refractory-lower-risk-myelodysplastic-syndrome-r-r2026-07-13T17:56:58.700Zhttps://www.appliedxl.com/news/r289-relapsed-or-refractory-r-r-lower-risk-myelodysplastic-syndrome2026-07-13T17:52:59.963Zhttps://www.appliedxl.com/news/ractigen-therapeutics-rag-17-2026-readout2026-07-15T13:05:08.491Zhttps://www.appliedxl.com/news/rademikibart-acute-copd-exacerbations-readout-20262026-07-05T00:06:19.265Zhttps://www.appliedxl.com/news/rademikibart-acute-exacerbations-in-participants-with-asthma-and-type2026-07-14T17:01:18.712Zhttps://www.appliedxl.com/news/ragistomig-solid-tumors-readout-20262026-07-13T17:58:55.538Zhttps://www.appliedxl.com/news/rani-therapeutics-holdings-inc-rt-114-delivering-pg-102-2026-readout2026-07-15T12:24:52.492Zhttps://www.appliedxl.com/news/rap-219-bipolar-mania-readout-20262026-07-13T17:42:13.055Zhttps://www.appliedxl.com/news/rap-219-drug-resistant-focal-onset-seizures-readout-20262026-07-13T17:40:34.806Zhttps://www.appliedxl.com/news/rb042-healthy-volunteers-and-healthy-smokers-readout-20262026-07-13T18:02:08.277Zhttps://www.appliedxl.com/news/recent-resultshttps://www.appliedxl.com/news/regenxbio-inc-surabgene-lomparvovec-2026-scientific-conference2026-07-14T16:36:40.952Zhttps://www.appliedxl.com/news/regenxbio-inc-surabgene-lomparvovec-2026-scientific-conference-e726c42026-07-14T16:48:02.153Zhttps://www.appliedxl.com/news/regulatoryhttps://www.appliedxl.com/news/relutrigine-scn2a-and-scn8a-developmental-and-epileptic2026-07-13T18:55:03.895Zhttps://www.appliedxl.com/news/rese-cel-resecabtagene-autoleucel-generalized-myasthenia-gravis-gmg2026-07-13T18:47:57.911Zhttps://www.appliedxl.com/news/resilia-tissue-readout-20262026-07-13T17:51:57.370Zhttps://www.appliedxl.com/news/revita-post-glp-1-weight-maintenance-readout-20262026-07-13T17:32:45.750Zhttps://www.appliedxl.com/news/revita-post-glp-1-weight-maintenance-readout-2026-a237762026-07-13T18:08:47.512Zhttps://www.appliedxl.com/news/rezpegaldesleukin-moderate-to-severe-atopic-dermatitis-scientific2026-07-14T16:53:33.108Zhttps://www.appliedxl.com/news/rgx-202-duchenne-muscular-dystrophy-fda-submission-20262026-07-13T17:34:30.147Zhttps://www.appliedxl.com/news/roche-enicepatide-nct07670416-phase3-china2026-07-03T17:11:44.413Zhttps://www.appliedxl.com/news/rusfertide-polycythemia-vera-fda-decision-20262026-07-13T17:38:14.857Zhttps://www.appliedxl.com/news/sabirnetug-acu193-early-alzheimers-disease-readout-20262026-07-14T17:01:16.221Zhttps://www.appliedxl.com/news/salubris-sacubitril-allisartan-amlodipine-hypertension-20252026-07-15T15:25:17.851Zhttps://www.appliedxl.com/news/salubris-sacubitril-allisartan-hypertension-20262026-07-15T15:25:10.054Zhttps://www.appliedxl.com/news/sat-3247-duchenne-muscular-dystrophy-dmd-readout-20262026-07-13T17:47:58.673Zhttps://www.appliedxl.com/news/satellos-bioscience-inc-sat-3247-2026-readout2026-07-14T16:24:16.218Zhttps://www.appliedxl.com/news/savara-inc-molbreevi-2027-fda-decision2026-07-13T18:50:28.448Zhttps://www.appliedxl.com/news/selective-cytopheretic-device-scd-therapy-acute-kidney-injury-aki-in2026-07-13T18:40:42.460Zhttps://www.appliedxl.com/news/selinexor-multiple-myeloma-readout-20262026-07-03T14:37:10.325Zhttps://www.appliedxl.com/news/sep-479-hypoparathyroidism-readout-20262026-07-13T17:51:50.455Zhttps://www.appliedxl.com/news/setmelanotide-acquired-hypothalamic-obesity-fda-decision-20262026-07-13T18:43:26.170Zhttps://www.appliedxl.com/news/shenzhen-core-medical-corvad-right-heart-failure-trial-20262026-07-15T15:25:11.760Zhttps://www.appliedxl.com/news/shionogi-s-892216-renal-impairment-phase-1-completion2026-07-13T15:45:03.909Zhttps://www.appliedxl.com/news/shionogi-s-892216-renal-impairment-phase1-20262026-07-13T15:45:06.951Zhttps://www.appliedxl.com/news/shy-therapeutics-shy-onc6-phase-1-20262026-07-15T15:35:14.965Zhttps://www.appliedxl.com/news/sion-451-healthy-volunteers-readout-2026-c0679d2026-07-13T17:52:41.279Zhttps://www.appliedxl.com/news/solriamfetol-binge-eating-disorder-bed-readout-20262026-07-14T18:46:16.054Zhttps://www.appliedxl.com/news/solriamfetol-shift-work-disorder-swd-readout-20262026-07-03T14:35:21.274Zhttps://www.appliedxl.com/news/sonelokimab-hidradenitis-suppurativa-fda-submission-20262026-07-13T17:43:39.274Zhttps://www.appliedxl.com/news/sonelokimab-m1095-hidradenitis-suppurativa-hs-readout-20262026-07-15T21:18:09.221Zhttps://www.appliedxl.com/news/sonoclear-system-glioma-scientific-conference-presentation-20262026-07-13T17:33:03.349Zhttps://www.appliedxl.com/news/spark-biomedical-transcutaneous-auricular-neurostimulation-tan2026-07-14T16:10:52.680Zhttps://www.appliedxl.com/news/spr-sprint-pns-system-2026-scientific-conference-presentation2026-07-14T13:24:58.385Zhttps://www.appliedxl.com/news/spy003-moderately-to-severely-active-ulcerative-colitis-readout-20262026-07-13T17:42:43.372Zhttps://www.appliedxl.com/news/spy072-moderate-to-severely-active-rheumatoid-arthritis-psoriatic2026-07-13T18:37:36.452Zhttps://www.appliedxl.com/news/spy072-rheumatoid-arthritis-ra-readout-20262026-07-13T17:33:04.254Zhttps://www.appliedxl.com/news/staidson-stsa-1002-phase-1-c5a-antibody2026-07-03T20:05:33.852Zhttps://www.appliedxl.com/news/stapokibart-atopic-dermatitis-eosinophils-20262026-07-15T19:44:41.548Zhttps://www.appliedxl.com/news/star-0215-hereditary-angioedema-hae-readout-20262026-07-13T18:48:04.061Zhttps://www.appliedxl.com/news/sumgen-sg1827-phase1-completion-date-20262026-07-15T15:35:11.180Zhttps://www.appliedxl.com/news/suncadia-adalimumab-nsclc-phase2-20262026-07-15T15:25:27.454Zhttps://www.appliedxl.com/news/symptomatic-hallux-valgus-readout-20262026-07-13T17:51:13.499Zhttps://www.appliedxl.com/news/syx-5219-moderate-to-severe-atopic-dermatitis-readout-20262026-07-13T17:37:44.976Zhttps://www.appliedxl.com/news/tafenoquine-babesiosis-readout-2026-8c7fae2026-07-13T17:51:12.652Zhttps://www.appliedxl.com/news/tango-tng260-nct05887492-enrollment-complete-20262026-07-06T15:56:31.051Zhttps://www.appliedxl.com/news/taplucainium-refractory-or-unexplained-chronic-cough-rcc-ucc-readout2026-07-14T16:29:00.950Zhttps://www.appliedxl.com/news/teas-breast-cancer-postoperative-pain-sleep-20262026-07-15T20:14:55.436Zhttps://www.appliedxl.com/news/tectonic-therapeutic-inc-tx45-2027-readout2026-07-13T18:14:54.484Zhttps://www.appliedxl.com/news/tev-408-celiac-disease-readout-20262026-07-13T17:34:25.664Zhttps://www.appliedxl.com/news/tg4050-operable-head-and-neck-squamous-cell-carcinoma-hnscc-readout2026-07-13T18:27:25.644Zhttps://www.appliedxl.com/news/third-generation-egfr-tki-network-meta-analysis-20262026-07-14T20:44:53.348Zhttps://www.appliedxl.com/news/thn391-diabetic-macular-edema-dme-readout-20262026-07-13T18:10:15.148Zhttps://www.appliedxl.com/news/tibulizumab-hidradenitis-suppurativa-readout-20262026-07-13T17:43:21.039Zhttps://www.appliedxl.com/news/tiragolumab-atezolizumab-safety-meta-analysis-20262026-07-14T19:24:45.866Zhttps://www.appliedxl.com/news/tivoxavir-marboxil-txm-human-influenza-challenge-study-fda-submission2026-07-13T17:42:31.687Zhttps://www.appliedxl.com/news/tiximed-inc-tix100-2026-readout2026-07-14T16:25:37.184Zhttps://www.appliedxl.com/news/tiziana-foralumab-banyan-als-trial-20262026-07-07T15:25:36.449Zhttps://www.appliedxl.com/news/tlx101-px-characterization-of-recurrent-or-progressive-glioma-from2026-07-13T17:32:09.874Zhttps://www.appliedxl.com/news/tn-201-mybpc3-associated-hypertrophic-cardiomyopathy-hcm-scientific2026-07-13T18:24:40.926Zhttps://www.appliedxl.com/news/tolerogenixx-mic-lx-2026-readout2026-07-14T16:04:58.458Zhttps://www.appliedxl.com/news/tovecimig-ctx-009-unresectable-advanced-metastatic-or-recurrent2026-07-13T18:41:23.759Zhttps://www.appliedxl.com/news/tp53-wild-type-endometrial-cancer-readout-20262026-07-14T17:02:09.827Zhttps://www.appliedxl.com/news/travere-therapeutics-pegtibatinase-tvt-058-2027-readout2026-07-03T14:16:32.504Zhttps://www.appliedxl.com/news/treprostinil-palmitil-inhalation-powder-tpip-pulmonary-arterial2026-07-13T18:47:05.578Zhttps://www.appliedxl.com/news/tris-pharma-cebranopadol-2026-readout2026-07-14T16:22:57.714Zhttps://www.appliedxl.com/news/tris-pharma-cebranopadol-2026-readout-2f733f2026-07-14T16:22:53.330Zhttps://www.appliedxl.com/news/trispecific-car-t-cd19-cd20-cd22-first-in-human-20262026-07-14T19:14:51.321Zhttps://www.appliedxl.com/news/triv-509-moderate-to-severe-atopic-dermatitis-readout-20262026-07-13T17:38:40.237Zhttps://www.appliedxl.com/news/tulsa-procedure-tulsa-pro-level-i-prostate-cancer-readout-20262026-07-13T17:37:10.976Zhttps://www.appliedxl.com/news/tx45-pulmonary-hypertension-in-heart-failure-with-preserved-ejection2026-07-13T17:51:11.224Zhttps://www.appliedxl.com/news/ucb-bimekizumab-2026-3-year-data2026-07-03T17:10:02.136Zhttps://www.appliedxl.com/news/unicycive-oxylanthanum-carbonate-olc-2026-fda2026-07-15T21:10:21.448Zhttps://www.appliedxl.com/news/uniqure-n-v-amt-130-2026-fda-submission2026-07-13T17:36:14.308Zhttps://www.appliedxl.com/news/upcoming-readoutshttps://www.appliedxl.com/news/uppsala-university-hospital-up421-2025-readout-4ec57d2026-07-14T16:05:20.180Zhttps://www.appliedxl.com/news/vanda-pharmaceuticals-inc-bysanti-milsaperidone-2027-readout2026-07-13T18:05:34.009Zhttps://www.appliedxl.com/news/varegacestat-progressing-desmoid-tumors-scientific-conference2026-07-13T17:34:41.915Zhttps://www.appliedxl.com/news/vaxart-inc-oral-pill-vaccine-2027-readout2026-07-03T14:12:57.906Zhttps://www.appliedxl.com/news/vclas-system-monomorphic-ventricular-tachycardia-mmvt-fda-decision2026-07-13T18:09:49.550Zhttps://www.appliedxl.com/news/ve303-prevention-of-recurrent-clostridioides-difficile-infection-cdi2026-07-13T17:37:36.200Zhttps://www.appliedxl.com/news/vera-therapeutics-atacicept-2027-readout2026-07-03T14:29:13.921Zhttps://www.appliedxl.com/news/veradermics-incorporated-vdphl01-2026-readout-83436b2026-07-14T23:05:29.609Zhttps://www.appliedxl.com/news/veradermics-incorporated-vdphl01-2026-readout-83436b-ff17f62026-07-15T11:15:27.639Zhttps://www.appliedxl.com/news/veru-inc-enobosarm-2024-readout-d754b62026-07-14T16:43:59.566Zhttps://www.appliedxl.com/news/veru-inc-enobosarm-2027-readout2026-07-13T18:48:54.777Zhttps://www.appliedxl.com/news/viaskin-peanut-patch-peanut-allergic-toddlers-aged-1-to-3-years2026-07-13T18:44:16.720Zhttps://www.appliedxl.com/news/viaskin-peanut-patch-peanut-allergic-toddlers-aged-1-to-3-years-fda2026-07-13T18:44:23.325Zhttps://www.appliedxl.com/news/vigonvita-vv119-schizophrenia-phase2-20262026-07-15T15:25:07.383Zhttps://www.appliedxl.com/news/vigonvita-vv913-food-effect-phase1-20262026-07-14T15:25:44.241Zhttps://www.appliedxl.com/news/vigonvita-vv913-phase1-mad-20262026-07-14T15:25:01.901Zhttps://www.appliedxl.com/news/vmt01-melanoma-readout-20262026-07-13T18:37:44.347Zhttps://www.appliedxl.com/news/vonaprument-geographic-atrophy-ga-readout-20262026-07-13T17:51:02.933Zhttps://www.appliedxl.com/news/vormatrigine-focal-onset-seizures-readout-20262026-07-15T21:10:20.763Zhttps://www.appliedxl.com/news/voronoi-vrn110755-nsclc-trial-20262026-07-13T15:45:47.847Zhttps://www.appliedxl.com/news/voxzogo-vosoritide-hypochondroplasia-fda-submission-20262026-07-13T17:35:36.915Zhttps://www.appliedxl.com/news/vtp-1000-celiac-disease-readout-2026-a309de2026-07-13T18:25:32.718Zhttps://www.appliedxl.com/news/vx-670-myotonic-dystrophy-type-1-dm1-readout-20262026-07-13T17:43:41.001Zhttps://www.appliedxl.com/news/vyd2311-pre-exposure-prophylaxis-prevention-of-symptomatic-covid-192026-07-14T16:59:08.374Zhttps://www.appliedxl.com/news/vyvgart-efgartigimod-alfa-and-hyaluronidase-qvfc-ocular-myasthenia2026-07-13T17:37:42.860Zhttps://www.appliedxl.com/news/welireg-belzutifan-and-keytruda-pembrolizumab-renal-cell-d092e82026-07-15T21:14:08.805Zhttps://www.appliedxl.com/news/winrevair-seeking-label-update-for-winrevair-pah-fda-decision-20262026-07-13T17:36:21.070Zhttps://www.appliedxl.com/news/xeltis-axess-2026-readout2026-07-14T16:27:03.465Zhttps://www.appliedxl.com/news/xt1061-hepatitis-b-phase-1a2026-07-15T20:24:53.560Zhttps://www.appliedxl.com/news/xvivo-heart-assist-transport-preservation-and-transport-of-extended2026-07-13T17:57:06.092Zhttps://www.appliedxl.com/news/yeztugo-lenacapavir-300-mg-tablet-pre-exposure-prophylaxis-prep-to2026-07-13T18:48:33.582Zhttps://www.appliedxl.com/news/z-1018-prevention-of-shingles-in-adults-aged-70-years-and-older2026-07-13T18:40:34.708Zhttps://www.appliedxl.com/news/zai-lab-zl-1310-2026-enrollment-increase2026-07-07T15:25:30.540Zhttps://www.appliedxl.com/news/zanzalintinib-in-combination-with-nivolumab-previously-untreated2026-07-04T00:06:15.548Zhttps://www.appliedxl.com/news/zenkuda-and-ksi-501-neovascular-age-related-macular-degeneration-wet2026-07-14T17:03:00.945Zhttps://www.appliedxl.com/news/zetomipzomib-active-lupus-nephritis-ln-readout-20262026-07-03T14:33:28.882Zhttps://www.appliedxl.com/news/zidesamtinib-ros1-mutation-positive-non-small-cell-lung-cancer-nsclc2026-07-13T18:55:43.272Zhttps://www.appliedxl.com/news/ziihera-zanidatamab-hrii-her2-positive-unresectable-locally-advanced2026-07-13T17:38:08.566Zhttps://www.appliedxl.com/news/zilganersen-alexander-disease-axd-fda-decision-20262026-07-13T17:32:08.791Zhttps://www.appliedxl.com/news/zilganersen-alexander-disease-axd-fda-decision-2026-0285b22026-07-13T18:40:16.381Zhttps://www.appliedxl.com/news/zilretta-osteoarthritis-pain-of-the-shoulder-readout-20262026-07-13T18:47:58.879Zhttps://www.appliedxl.com/news/zilurgisertib-fibrodysplasia-ossificans-progressiva-fop-fda-decision2026-07-13T18:55:33.008Zhttps://www.appliedxl.com/news/zipalertinib-locally-advanced-or-metastatic-non-small-cell-lung2026-07-13T18:48:54.439Zhttps://www.appliedxl.com/news/zl-1503-atopic-dermatitis-ad-readout-20262026-07-13T17:56:11.313Zhttps://www.appliedxl.com/news/zocilurtatug-pelitecan-zoci-first-line-es-sclc-combination-regimens2026-07-13T18:11:45.516Zhttps://www.appliedxl.com/news/zp9830-kv1-3-ion-channel-blocker-readout-20262026-07-13T18:24:52.945Zhttps://www.appliedxl.com/news/zumilokibart-apg777-mild-to-moderate-asthma-scientific-conference2026-07-13T17:48:45.037Z